The next generation biopharmaceuticals
Board of Directors
Robert Burns, Ph.D. Chairman
Robert is a board member of Targovax ASA (OSE:TRVX). He has been CEO of three antibody discovery & development companies (Celldex - CLDX:NASDAQ; Affitech A/S – AFFI:OMX; and 4-Antibody AG – Basel) leading successful private investor exits for all three companies. He was also Chairman of Haemostatix Ltd until the successful divestment of the company to Ergomed plc – ERGO:LSE. Previously he has served in commercial and business development leadership positions at Ludwig Cancer Research (US), Oxford Glycosciences plc (UK), British Biotechnology plc (UK), Applied biotechnology Inc (US), and Corning Glassworks (US & UK).
Mathias Uhlén, Ph.D. Deputy Chairman
Prof. Uhlén is a co-founder of Affibody AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. He is a Program Director of the Swedish Human Protein (HPA) program, funded by the Knut and Alice Wallenberg foundation, and a Board member of Atlas Antibodies AB (Chairman), Antibodypedia AB (Chairman), Bure AB, Novozymes AS, Atlasab Intressenter AB and SweTree Technologies AB.
Jonathan Knowles, Prof., Ph.D. Director
Jonathan Knowles is currently professor in personalized health care at the Finnish Institute for Molecular Medicine at the University of Helsinki, and visiting chair at the University of Oxford. He also serves on the board of a number of biotech companies including Immunocore Ltd. (Chairman), Adaptimmune Ltd (Chairman) and Caris Life Sciences. In his most recent executive role he was president of group research at Roche and member of Roche’s Corporate Executive Committee. Dr Knowles was also a member of the Genentech Board for 12 years and a member of the Chugai Board for seven years.
Jakob Lindberg, Med. Lic. Director
Jakob Lindberg is CEO of Oncopeptides AB and board member of Atlas Antibodies AB och Alligator Bioscience AB. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. He started his career as an analyst with Merrill Lynch in London and moved to consultancy with McKinsey in Stockholm, followed by a period in Gothenburg as CEO and co-founder of Cellectricon AB.
Hanna Eiderbrant Director
Hanna Eiderbrant is an employee of Patricia Industries with engagement in multiple portfolio companies as well as scouting for new investment opportunities. She has broad experience of business development and corporate transactions within multiple industries. Prior to joining Patricia Industries she was an Investment Manager at Ratos AB and a management consultant at A.T. Kearney. Hanna has a M.Sc. in Business and Economics from the Royal Institute of Technology (KTH) and the University of Stockholm.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Year-end report (February 24, 2017)